GB768821A
(en)
|
1954-05-17 |
1957-02-20 |
Gruenenthal Chemie |
Novel products of the amino-piperidine-2, 6-dione series
|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
US4994443A
(en)
|
1982-12-20 |
1991-02-19 |
The Children's Medical Center Corporation |
Inhibition of angiogenesis
|
US5001116A
(en)
|
1982-12-20 |
1991-03-19 |
The Children's Medical Center Corporation |
Inhibition of angiogenesis
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
US5391485A
(en)
|
1985-08-06 |
1995-02-21 |
Immunex Corporation |
DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
|
US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
JPS63500636A
(ja)
|
1985-08-23 |
1988-03-10 |
麒麟麦酒株式会社 |
多分化能性顆粒球コロニー刺激因子をコードするdna
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
US5360352A
(en)
|
1992-12-24 |
1994-11-01 |
The Whitaker Corporation |
Wire retainer for current mode coupler
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
US5463063A
(en)
|
1993-07-02 |
1995-10-31 |
Celgene Corporation |
Ring closure of N-phthaloylglutamines
|
WO1995003009A1
(en)
|
1993-07-22 |
1995-02-02 |
Oculex Pharmaceuticals, Inc. |
Method of treatment of macular degeneration
|
WO1995003807A1
(en)
|
1993-07-27 |
1995-02-09 |
The University Of Sydney |
Treatment of age-related macular degeneration
|
DE4422237A1
(de)
|
1994-06-24 |
1996-01-04 |
Gruenenthal Gmbh |
Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
IT1274549B
(it)
|
1995-05-23 |
1997-07-17 |
Indena Spa |
Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
|
US5800819A
(en)
|
1996-01-25 |
1998-09-01 |
National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology |
Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
WO1998003502A1
(en)
|
1996-07-24 |
1998-01-29 |
Celgene Corporation |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels
|
US6015803A
(en)
|
1998-05-04 |
2000-01-18 |
Wirostko; Emil |
Antibiotic treatment of age-related macular degeneration
|
US6225348B1
(en)
|
1998-08-20 |
2001-05-01 |
Alfred W. Paulsen |
Method of treating macular degeneration with a prostaglandin derivative
|
US6001368A
(en)
|
1998-09-03 |
1999-12-14 |
Protein Technologies International, Inc. |
Method for inhibiting or reducing the risk of macular degeneration
|
US7182953B2
(en)
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
JP2004526419A
(ja)
|
2000-10-16 |
2004-09-02 |
フィロス インク. |
抗体模倣物および他の結合タンパク質のためのタンパク質骨格
|
NZ526683A
(en)
|
2000-11-30 |
2008-03-28 |
Childrens Medical Center |
Synthesis of 4-amino-thalidomide and its enantiomers that are suitable for inhibiting angiogenesis
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
ES2172474B1
(es)
|
2001-03-01 |
2004-01-16 |
Fundacion Universitaria San Pa |
Derivados de glutarimida como agentes terapeuticos.
|
US20030082630A1
(en)
|
2001-04-26 |
2003-05-01 |
Maxygen, Inc. |
Combinatorial libraries of monomer domains
|
WO2003007955A2
(en)
|
2001-07-20 |
2003-01-30 |
Cancer Research Technology Limited |
Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
|
CN1511420A
(zh)
|
2001-11-09 |
2004-07-07 |
松下电器产业株式会社 |
运动图像编码方法和装置
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
US20050203142A1
(en)
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US20040091455A1
(en)
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US20050100529A1
(en)
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
WO2005049613A1
(en)
|
2003-11-14 |
2005-06-02 |
Merck Sharp & Dohme Limited |
Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
|
US20050143420A1
(en)
|
2003-12-02 |
2005-06-30 |
Moutouh-De Parseval Laure |
Methods and compositions for the treatment and management of hemoglobinopathy and anemia
|
US20050143344A1
(en)
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
CN1956718A
(zh)
|
2004-03-22 |
2007-05-02 |
细胞基因公司 |
用于治疗和控制皮肤疾病和病症的含免疫调节化合物的组合物和使用方法
|
US20050222209A1
(en)
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
CA2563810A1
(en)
|
2004-04-23 |
2005-11-10 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
|
CA2586950A1
(en)
|
2004-11-12 |
2006-05-18 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
|
US20060234299A1
(en)
|
2004-11-16 |
2006-10-19 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
US20060122228A1
(en)
|
2004-11-23 |
2006-06-08 |
Zeldis Jerome B |
Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
|
US20080051379A1
(en)
|
2004-12-01 |
2008-02-28 |
Trustees Of Boston University |
Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms
|
NZ555886A
(en)
|
2004-12-01 |
2009-12-24 |
Celgene Corp |
Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders
|
GB0506147D0
(en)
|
2005-03-24 |
2005-05-04 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB0509573D0
(en)
|
2005-05-11 |
2005-06-15 |
Merck Sharp & Dohme |
Therapeutic compounds
|
AU2006244027A1
(en)
|
2005-05-11 |
2006-11-16 |
Merck Sharp & Dohme Limited |
2,3-substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilloid-1 receptor (VR1)
|
CN101415688A
(zh)
|
2006-04-05 |
2009-04-22 |
阿斯利康(瑞典)有限公司 |
具有b-raf抑制活性的喹唑啉酮衍生物
|
JP2009532449A
(ja)
|
2006-04-05 |
2009-09-10 |
アストラゼネカ アクチボラグ |
抗癌活性のある置換キナゾリン
|
CN101421253A
(zh)
|
2006-04-18 |
2009-04-29 |
阿斯利康(瑞典)有限公司 |
喹唑啉-4-酮衍生物、其制备方法及含有它们的药用组合物
|
ME02829B
(me)
|
2006-09-26 |
2018-01-20 |
Celgene Corp |
5-supstituirani derivati kinazolinona kao sredstva protiv raka
|
ES2523925T3
(es)
|
2007-09-26 |
2014-12-02 |
Celgene Corporation |
Derivados de quinazolinona sustituidos en posición 6, 7 u 8 y composiciones que los contienen y métodos de uso de los mismos
|
US8354417B2
(en)
|
2007-09-26 |
2013-01-15 |
Celgene Corporation |
Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same
|
TWI475014B
(zh)
|
2009-09-17 |
2015-03-01 |
Scinopharm Taiwan Ltd |
固體形態的3-(4-胺基-1-側氧基-1,3-二氫-異吲哚-2-基)-哌啶-2,6-二酮及其製造方法
|
WO2011047129A1
(en)
|
2009-10-15 |
2011-04-21 |
Southern Research Institute |
Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
|
WO2012027065A2
(en)
|
2010-08-27 |
2012-03-01 |
Celgene Corporation |
Combination therapy for treatment of disease
|
WO2012066330A1
(en)
|
2010-11-17 |
2012-05-24 |
Heptares Therapeutics Limited |
Compounds useful as a2a receptor inhibitors
|
AU2011329619A1
(en)
|
2010-11-18 |
2013-05-02 |
Deuteria Pharmaceuticals, Inc. |
3-deutero-pomalidomide
|
CN107375293A
(zh)
|
2011-03-11 |
2017-11-24 |
细胞基因公司 |
利用3‑(5‑氨基‑2‑甲基‑4‑氧‑4h‑喹唑啉‑3‑基)‑哌啶‑2,6‑二酮治疗癌症的方法
|
RS56770B1
(sr)
|
2011-03-11 |
2018-04-30 |
Celgene Corp |
Čvrste forme 3-(5-amino-2-metil-4-okso-4h-hinazolin-3-il)-piperidin-2,6-diona i njihove farmaceutske smeše i upotrebe
|
KR20140024914A
(ko)
|
2011-04-29 |
2014-03-03 |
셀진 코포레이션 |
예측인자로 세레브론을 사용하는 암 및 염증성 질환의 치료를 위한 방법
|
CN104737021A
(zh)
|
2012-01-13 |
2015-06-24 |
细胞基因公司 |
用于治疗肝细胞癌的生物标志物
|
ES2699810T3
(es)
|
2012-06-29 |
2019-02-12 |
Celgene Corp |
Métodos para determinar la eficacia de fármacos usando proteínas asociadas a cereblon
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
US9682952B2
(en)
|
2012-09-04 |
2017-06-20 |
Celgene Corporation |
Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl) piperidine-2-6-dione and methods of preparation thereof
|
BR112015005243A2
(pt)
|
2012-09-10 |
2017-07-04 |
Celgene Corp |
métodos para o tratamento de câncer de mama localmente avançado
|
JP6359563B2
(ja)
|
2013-01-14 |
2018-07-18 |
デュートルクス・リミテッド・ライアビリティ・カンパニーDeuteRx, LLC |
3−(5置換−4−オキソキナゾリン−3(4h)−イル)−3−ジュウテロピペリジン−2,6−ジオン誘導体
|
KR20150126618A
(ko)
|
2013-03-14 |
2015-11-12 |
셀진 코포레이션 |
아프레밀라스트를 사용하는 건선성 관절염의 치료
|
TW201521725A
(zh)
|
2013-04-17 |
2015-06-16 |
Signal Pharm Llc |
使用tor激酶抑制劑組合療法以治療癌症之方法
|
CN105358177B
(zh)
|
2013-04-17 |
2018-11-23 |
西格诺药品有限公司 |
包含tor激酶抑制剂和imid化合物的联合疗法用于治疗癌症
|
TWI654979B
(zh)
|
2013-04-17 |
2019-04-01 |
美商標誌製藥公司 |
使用tor激酶抑制劑組合療法以治療癌症之方法
|
RS56565B1
(sr)
|
2013-05-01 |
2018-02-28 |
Celgene Corp |
Sinteza 3-(5-amino-2-metil-4-oksohinazolin-3(4h)-il)piperidin-2,6-diona
|
JP2016521280A
(ja)
|
2013-05-03 |
2016-07-21 |
セルジーン コーポレイション |
併用療法を用いて癌を治療する方法
|
IL278381B1
(en)
|
2013-12-06 |
2024-04-01 |
Celgene Corp |
Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
WO2015108889A1
(en)
|
2014-01-15 |
2015-07-23 |
Celgene Corporation |
Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
|
WO2015107196A1
(en)
|
2014-01-20 |
2015-07-23 |
Institut Curie |
Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation
|
EP3116872A4
(en)
|
2014-03-14 |
2017-08-30 |
Calithera Biosciences, Inc. |
Combination therapy with glutaminase inhibitors
|
KR20210132233A
(ko)
|
2014-04-14 |
2021-11-03 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
|
JP6640126B2
(ja)
|
2014-06-27 |
2020-02-05 |
セルジーン コーポレイション |
セレブロン及び他のe3ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
|
MX2017000366A
(es)
|
2014-07-11 |
2017-04-27 |
Celgene Corp |
Terapia de combinacion para el cancer.
|
WO2016014890A1
(en)
|
2014-07-24 |
2016-01-28 |
Calithera Biosciences, Inc. |
Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
|
EP3193876B1
(en)
|
2014-08-07 |
2022-01-12 |
Calithera Biosciences Inc. |
Crystal forms of glutaminase inhibitors
|
EP3188745A1
(en)
|
2014-08-15 |
2017-07-12 |
Celgene Corporation |
Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
|
EP3207151A4
(en)
|
2014-10-13 |
2018-07-04 |
Celgene Corporation |
Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
US9717745B2
(en)
|
2015-03-19 |
2017-08-01 |
Zhejiang DTRM Biopharma Co. Ltd. |
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
|
WO2016153948A1
(en)
|
2015-03-20 |
2016-09-29 |
Deuterx, Llc |
Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders
|
US10450299B2
(en)
|
2015-03-25 |
2019-10-22 |
Centre National De La Recherche Scientifique (Cnrs) |
Substituted quinazoline derivatives as DNA methyltransferase inhibitors
|
TW201642857A
(zh)
|
2015-04-06 |
2016-12-16 |
西建公司 |
以組合療法治療肝細胞癌
|